SCHEMBL3582514

SCHEMBL3582514

CNc1ncc(F)cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ASPH Q12797 1/20 0.41
KDM8 Q8N371 1/20 0.41
AGBL2 Q5U5Z8 1/20 0.40
JAK2 O60674 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
DHODH Q02127 3/20 0.39
KDM4C Q9H3R0 1/20 0.39
KEAP1 Q14145 2/20 0.38
NFE2L2 Q16236 1/20 0.37
HCAR3 P49019 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31563400 0.86 SMN1; SMN2 (0.43) CHRNA7KDM4EAGBL2JAK2
SCHEMBL2581291 0.83 OPRK1 (0.45) CHRNA7KDM4EJAK2ALDH1A1
SCHEMBL3576168 0.81 JAK2 (0.43) CHRNA7KDM4EASPHKDM8AGBL2
SCHEMBL17363110 0.81 PTGER4 (0.39) KDM4EASPHKDM8AGBL2HCAR2
SCHEMBL3570827 0.80 DHODH (0.44) KDM4EHCAR2DHODHKDM4CHCAR3
SCHEMBL15556556 0.79 KDM4C (0.39) CHRNA7KDM4EASPHKDM8DHODH
SCHEMBL2067917 0.79 OPRK1 (0.41) KDM4EHCAR2KDM4CHCAR3ALDH1A1
SCHEMBL1397722 0.79 DHODH (0.51) CHRNA7KDM4EHCAR2DHODHKDM4C
SCHEMBL15636527 0.78 KDM4C (0.47) CHRNA7KDM4EASPHKDM8AGBL2
SCHEMBL15636037 0.77 DHODH (0.58) JAK2DHODHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
CN-101379036-B Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE 2011-06-01 CN disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
CN-101379036-A Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE (CH) 2009-03-04 CN disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-1995007909-A1 ALKYL-1-ALKYL-4-HYDROXY-2-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATES AS ANTI-RHEUMATIC AGENTS KNOLL AG (DE) 1995-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC CHRNA7 626/4885KDM4E 1828/4885ASPH 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.